nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—Rhinorrhoea—Sorafenib—liver cancer	0.0315	0.0315	CcSEcCtD
Apraclonidine—Nasopharyngitis—Sorafenib—liver cancer	0.0166	0.0166	CcSEcCtD
Apraclonidine—Lacrimation—Epirubicin—liver cancer	0.016	0.0161	CcSEcCtD
Apraclonidine—Abdominal discomfort—Sorafenib—liver cancer	0.0153	0.0154	CcSEcCtD
Apraclonidine—Lacrimation—Doxorubicin—liver cancer	0.0148	0.0149	CcSEcCtD
Apraclonidine—Keratitis—Epirubicin—liver cancer	0.0145	0.0146	CcSEcCtD
Apraclonidine—Parosmia—Epirubicin—liver cancer	0.0145	0.0146	CcSEcCtD
Apraclonidine—Infestation NOS—Sorafenib—liver cancer	0.0143	0.0143	CcSEcCtD
Apraclonidine—Infestation—Sorafenib—liver cancer	0.0143	0.0143	CcSEcCtD
Apraclonidine—Parosmia—Doxorubicin—liver cancer	0.0135	0.0135	CcSEcCtD
Apraclonidine—Keratitis—Doxorubicin—liver cancer	0.0135	0.0135	CcSEcCtD
Apraclonidine—Haemorrhage—Sorafenib—liver cancer	0.0128	0.0128	CcSEcCtD
Apraclonidine—Angiopathy—Sorafenib—liver cancer	0.0116	0.0116	CcSEcCtD
Apraclonidine—Mediastinal disorder—Sorafenib—liver cancer	0.0115	0.0116	CcSEcCtD
Apraclonidine—Arrhythmia—Sorafenib—liver cancer	0.0114	0.0115	CcSEcCtD
Apraclonidine—Mental disorder—Sorafenib—liver cancer	0.0112	0.0112	CcSEcCtD
Apraclonidine—Erythema—Sorafenib—liver cancer	0.0112	0.0112	CcSEcCtD
Apraclonidine—Dysgeusia—Sorafenib—liver cancer	0.0109	0.0109	CcSEcCtD
Apraclonidine—Vasodilation procedure—Epirubicin—liver cancer	0.0107	0.0107	CcSEcCtD
Apraclonidine—Vasodilation—Epirubicin—liver cancer	0.0107	0.0107	CcSEcCtD
Apraclonidine—Lacrimation increased—Epirubicin—liver cancer	0.0102	0.0102	CcSEcCtD
Apraclonidine—Syncope—Sorafenib—liver cancer	0.01	0.01	CcSEcCtD
Apraclonidine—Vasodilation—Doxorubicin—liver cancer	0.00993	0.00994	CcSEcCtD
Apraclonidine—Vasodilation procedure—Doxorubicin—liver cancer	0.00993	0.00994	CcSEcCtD
Apraclonidine—Inflammation—Epirubicin—liver cancer	0.00972	0.00973	CcSEcCtD
Apraclonidine—Coordination abnormal—Epirubicin—liver cancer	0.0096	0.00961	CcSEcCtD
Apraclonidine—Myalgia—Sorafenib—liver cancer	0.0095	0.00951	CcSEcCtD
Apraclonidine—Lacrimation increased—Doxorubicin—liver cancer	0.00947	0.00948	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00943	0.00944	CcSEcCtD
Apraclonidine—Dermatitis contact—Epirubicin—liver cancer	0.00932	0.00933	CcSEcCtD
Apraclonidine—Dry mouth—Sorafenib—liver cancer	0.00929	0.0093	CcSEcCtD
Apraclonidine—Infection—Sorafenib—liver cancer	0.00905	0.00905	CcSEcCtD
Apraclonidine—Inflammation—Doxorubicin—liver cancer	0.009	0.00901	CcSEcCtD
Apraclonidine—Nervous system disorder—Sorafenib—liver cancer	0.00893	0.00894	CcSEcCtD
Apraclonidine—Coordination abnormal—Doxorubicin—liver cancer	0.00889	0.0089	CcSEcCtD
Apraclonidine—Skin disorder—Sorafenib—liver cancer	0.00884	0.00885	CcSEcCtD
Apraclonidine—Dry eye—Epirubicin—liver cancer	0.00871	0.00872	CcSEcCtD
Apraclonidine—Dermatitis contact—Doxorubicin—liver cancer	0.00862	0.00863	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00829	0.0083	CcSEcCtD
Apraclonidine—Abnormal vision—Epirubicin—liver cancer	0.00823	0.00823	CcSEcCtD
Apraclonidine—Dyspnoea—Sorafenib—liver cancer	0.00812	0.00813	CcSEcCtD
Apraclonidine—Dry eye—Doxorubicin—liver cancer	0.00806	0.00807	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Sorafenib—liver cancer	0.00786	0.00787	CcSEcCtD
Apraclonidine—Fatigue—Sorafenib—liver cancer	0.00785	0.00786	CcSEcCtD
Apraclonidine—Pain—Sorafenib—liver cancer	0.00779	0.00779	CcSEcCtD
Apraclonidine—Constipation—Sorafenib—liver cancer	0.00779	0.00779	CcSEcCtD
Apraclonidine—Abnormal vision—Doxorubicin—liver cancer	0.00761	0.00762	CcSEcCtD
Apraclonidine—Eye pain—Epirubicin—liver cancer	0.00758	0.00759	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Sorafenib—liver cancer	0.00745	0.00745	CcSEcCtD
Apraclonidine—Abdominal pain—Sorafenib—liver cancer	0.0072	0.0072	CcSEcCtD
Apraclonidine—Eye pain—Doxorubicin—liver cancer	0.00702	0.00702	CcSEcCtD
Apraclonidine—Hypersensitivity—Sorafenib—liver cancer	0.00671	0.00671	CcSEcCtD
Apraclonidine—Face oedema—Epirubicin—liver cancer	0.00661	0.00662	CcSEcCtD
Apraclonidine—Asthenia—Sorafenib—liver cancer	0.00653	0.00654	CcSEcCtD
Apraclonidine—Pruritus—Sorafenib—liver cancer	0.00644	0.00645	CcSEcCtD
Apraclonidine—Diarrhoea—Sorafenib—liver cancer	0.00623	0.00624	CcSEcCtD
Apraclonidine—Nasopharyngitis—Epirubicin—liver cancer	0.00612	0.00613	CcSEcCtD
Apraclonidine—Face oedema—Doxorubicin—liver cancer	0.00612	0.00612	CcSEcCtD
Apraclonidine—Dizziness—Sorafenib—liver cancer	0.00602	0.00603	CcSEcCtD
Apraclonidine—Asthma—Epirubicin—liver cancer	0.00592	0.00592	CcSEcCtD
Apraclonidine—Vomiting—Sorafenib—liver cancer	0.00579	0.00579	CcSEcCtD
Apraclonidine—Dermatitis—Sorafenib—liver cancer	0.00574	0.00574	CcSEcCtD
Apraclonidine—Headache—Sorafenib—liver cancer	0.0057	0.00571	CcSEcCtD
Apraclonidine—Nasopharyngitis—Doxorubicin—liver cancer	0.00566	0.00567	CcSEcCtD
Apraclonidine—Asthma—Doxorubicin—liver cancer	0.00547	0.00548	CcSEcCtD
Apraclonidine—Nausea—Sorafenib—liver cancer	0.00541	0.00541	CcSEcCtD
Apraclonidine—Infestation NOS—Epirubicin—liver cancer	0.00528	0.00528	CcSEcCtD
Apraclonidine—Infestation—Epirubicin—liver cancer	0.00528	0.00528	CcSEcCtD
Apraclonidine—Conjunctivitis—Epirubicin—liver cancer	0.00513	0.00513	CcSEcCtD
Apraclonidine—Infestation NOS—Doxorubicin—liver cancer	0.00488	0.00489	CcSEcCtD
Apraclonidine—Infestation—Doxorubicin—liver cancer	0.00488	0.00489	CcSEcCtD
Apraclonidine—Bradycardia—Epirubicin—liver cancer	0.00482	0.00483	CcSEcCtD
Apraclonidine—Rhinitis—Epirubicin—liver cancer	0.00475	0.00475	CcSEcCtD
Apraclonidine—Conjunctivitis—Doxorubicin—liver cancer	0.00474	0.00475	CcSEcCtD
Apraclonidine—Haemorrhage—Epirubicin—liver cancer	0.00474	0.00474	CcSEcCtD
Apraclonidine—Pharyngitis—Epirubicin—liver cancer	0.0047	0.00471	CcSEcCtD
Apraclonidine—Oedema peripheral—Epirubicin—liver cancer	0.00467	0.00467	CcSEcCtD
Apraclonidine—Visual impairment—Epirubicin—liver cancer	0.00456	0.00457	CcSEcCtD
Apraclonidine—Bradycardia—Doxorubicin—liver cancer	0.00446	0.00447	CcSEcCtD
Apraclonidine—Eye disorder—Epirubicin—liver cancer	0.00443	0.00443	CcSEcCtD
Apraclonidine—Rhinitis—Doxorubicin—liver cancer	0.00439	0.0044	CcSEcCtD
Apraclonidine—Haemorrhage—Doxorubicin—liver cancer	0.00438	0.00439	CcSEcCtD
Apraclonidine—Pharyngitis—Doxorubicin—liver cancer	0.00435	0.00435	CcSEcCtD
Apraclonidine—Oedema peripheral—Doxorubicin—liver cancer	0.00432	0.00432	CcSEcCtD
Apraclonidine—Angiopathy—Epirubicin—liver cancer	0.0043	0.0043	CcSEcCtD
Apraclonidine—Mediastinal disorder—Epirubicin—liver cancer	0.00427	0.00427	CcSEcCtD
Apraclonidine—Arrhythmia—Epirubicin—liver cancer	0.00423	0.00424	CcSEcCtD
Apraclonidine—Visual impairment—Doxorubicin—liver cancer	0.00422	0.00423	CcSEcCtD
Apraclonidine—Mental disorder—Epirubicin—liver cancer	0.00415	0.00415	CcSEcCtD
Apraclonidine—Erythema—Epirubicin—liver cancer	0.00412	0.00413	CcSEcCtD
Apraclonidine—Eye disorder—Doxorubicin—liver cancer	0.0041	0.0041	CcSEcCtD
Apraclonidine—Tension—Epirubicin—liver cancer	0.00405	0.00405	CcSEcCtD
Apraclonidine—Dysgeusia—Epirubicin—liver cancer	0.00404	0.00404	CcSEcCtD
Apraclonidine—Nervousness—Epirubicin—liver cancer	0.004	0.00401	CcSEcCtD
Apraclonidine—Angiopathy—Doxorubicin—liver cancer	0.00398	0.00398	CcSEcCtD
Apraclonidine—Mediastinal disorder—Doxorubicin—liver cancer	0.00395	0.00395	CcSEcCtD
Apraclonidine—Arrhythmia—Doxorubicin—liver cancer	0.00391	0.00392	CcSEcCtD
Apraclonidine—Vision blurred—Epirubicin—liver cancer	0.00389	0.00389	CcSEcCtD
Apraclonidine—Mental disorder—Doxorubicin—liver cancer	0.00384	0.00384	CcSEcCtD
Apraclonidine—Ill-defined disorder—Epirubicin—liver cancer	0.00383	0.00383	CcSEcCtD
Apraclonidine—Erythema—Doxorubicin—liver cancer	0.00381	0.00382	CcSEcCtD
Apraclonidine—Tension—Doxorubicin—liver cancer	0.00374	0.00375	CcSEcCtD
Apraclonidine—Dysgeusia—Doxorubicin—liver cancer	0.00374	0.00374	CcSEcCtD
Apraclonidine—Malaise—Epirubicin—liver cancer	0.00372	0.00372	CcSEcCtD
Apraclonidine—Nervousness—Doxorubicin—liver cancer	0.00371	0.00371	CcSEcCtD
Apraclonidine—Syncope—Epirubicin—liver cancer	0.0037	0.0037	CcSEcCtD
Apraclonidine—Palpitations—Epirubicin—liver cancer	0.00364	0.00365	CcSEcCtD
Apraclonidine—Vision blurred—Doxorubicin—liver cancer	0.0036	0.0036	CcSEcCtD
Apraclonidine—Ill-defined disorder—Doxorubicin—liver cancer	0.00354	0.00354	CcSEcCtD
Apraclonidine—Chest pain—Epirubicin—liver cancer	0.00351	0.00351	CcSEcCtD
Apraclonidine—Myalgia—Epirubicin—liver cancer	0.00351	0.00351	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.00349	0.00349	CcSEcCtD
Apraclonidine—Discomfort—Epirubicin—liver cancer	0.00347	0.00347	CcSEcCtD
Apraclonidine—Malaise—Doxorubicin—liver cancer	0.00344	0.00344	CcSEcCtD
Apraclonidine—Dry mouth—Epirubicin—liver cancer	0.00343	0.00344	CcSEcCtD
Apraclonidine—Syncope—Doxorubicin—liver cancer	0.00342	0.00342	CcSEcCtD
Apraclonidine—Palpitations—Doxorubicin—liver cancer	0.00337	0.00337	CcSEcCtD
Apraclonidine—Oedema—Epirubicin—liver cancer	0.00336	0.00337	CcSEcCtD
Apraclonidine—Infection—Epirubicin—liver cancer	0.00334	0.00335	CcSEcCtD
Apraclonidine—Nervous system disorder—Epirubicin—liver cancer	0.0033	0.0033	CcSEcCtD
Apraclonidine—Skin disorder—Epirubicin—liver cancer	0.00327	0.00327	CcSEcCtD
Apraclonidine—Chest pain—Doxorubicin—liver cancer	0.00325	0.00325	CcSEcCtD
Apraclonidine—Myalgia—Doxorubicin—liver cancer	0.00325	0.00325	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.00323	0.00323	CcSEcCtD
Apraclonidine—Discomfort—Doxorubicin—liver cancer	0.00321	0.00321	CcSEcCtD
Apraclonidine—Dry mouth—Doxorubicin—liver cancer	0.00318	0.00318	CcSEcCtD
Apraclonidine—Oedema—Doxorubicin—liver cancer	0.00311	0.00312	CcSEcCtD
Apraclonidine—Infection—Doxorubicin—liver cancer	0.00309	0.0031	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Epirubicin—liver cancer	0.00307	0.00307	CcSEcCtD
Apraclonidine—Nervous system disorder—Doxorubicin—liver cancer	0.00305	0.00306	CcSEcCtD
Apraclonidine—Insomnia—Epirubicin—liver cancer	0.00304	0.00305	CcSEcCtD
Apraclonidine—Skin disorder—Doxorubicin—liver cancer	0.00302	0.00303	CcSEcCtD
Apraclonidine—Paraesthesia—Epirubicin—liver cancer	0.00302	0.00302	CcSEcCtD
Apraclonidine—Dyspnoea—Epirubicin—liver cancer	0.003	0.003	CcSEcCtD
Apraclonidine—Somnolence—Epirubicin—liver cancer	0.00299	0.00299	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Epirubicin—liver cancer	0.0029	0.00291	CcSEcCtD
Apraclonidine—Fatigue—Epirubicin—liver cancer	0.0029	0.0029	CcSEcCtD
Apraclonidine—Constipation—Epirubicin—liver cancer	0.00288	0.00288	CcSEcCtD
Apraclonidine—Pain—Epirubicin—liver cancer	0.00288	0.00288	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00284	0.00284	CcSEcCtD
Apraclonidine—Insomnia—Doxorubicin—liver cancer	0.00282	0.00282	CcSEcCtD
Apraclonidine—Paraesthesia—Doxorubicin—liver cancer	0.0028	0.0028	CcSEcCtD
Apraclonidine—Dyspnoea—Doxorubicin—liver cancer	0.00278	0.00278	CcSEcCtD
Apraclonidine—Feeling abnormal—Epirubicin—liver cancer	0.00277	0.00278	CcSEcCtD
Apraclonidine—Somnolence—Doxorubicin—liver cancer	0.00277	0.00277	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Epirubicin—liver cancer	0.00275	0.00275	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Doxorubicin—liver cancer	0.00269	0.00269	CcSEcCtD
Apraclonidine—Fatigue—Doxorubicin—liver cancer	0.00268	0.00269	CcSEcCtD
Apraclonidine—Constipation—Doxorubicin—liver cancer	0.00266	0.00267	CcSEcCtD
Apraclonidine—Pain—Doxorubicin—liver cancer	0.00266	0.00267	CcSEcCtD
Apraclonidine—Abdominal pain—Epirubicin—liver cancer	0.00266	0.00266	CcSEcCtD
Apraclonidine—Feeling abnormal—Doxorubicin—liver cancer	0.00257	0.00257	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Doxorubicin—liver cancer	0.00255	0.00255	CcSEcCtD
Apraclonidine—Hypersensitivity—Epirubicin—liver cancer	0.00248	0.00248	CcSEcCtD
Apraclonidine—Abdominal pain—Doxorubicin—liver cancer	0.00246	0.00246	CcSEcCtD
Apraclonidine—Asthenia—Epirubicin—liver cancer	0.00241	0.00242	CcSEcCtD
Apraclonidine—Pruritus—Epirubicin—liver cancer	0.00238	0.00238	CcSEcCtD
Apraclonidine—Diarrhoea—Epirubicin—liver cancer	0.0023	0.0023	CcSEcCtD
Apraclonidine—Hypersensitivity—Doxorubicin—liver cancer	0.00229	0.0023	CcSEcCtD
Apraclonidine—Asthenia—Doxorubicin—liver cancer	0.00223	0.00224	CcSEcCtD
Apraclonidine—Dizziness—Epirubicin—liver cancer	0.00223	0.00223	CcSEcCtD
Apraclonidine—Pruritus—Doxorubicin—liver cancer	0.0022	0.0022	CcSEcCtD
Apraclonidine—Vomiting—Epirubicin—liver cancer	0.00214	0.00214	CcSEcCtD
Apraclonidine—Diarrhoea—Doxorubicin—liver cancer	0.00213	0.00213	CcSEcCtD
Apraclonidine—Dermatitis—Epirubicin—liver cancer	0.00212	0.00212	CcSEcCtD
Apraclonidine—Headache—Epirubicin—liver cancer	0.00211	0.00211	CcSEcCtD
Apraclonidine—Dizziness—Doxorubicin—liver cancer	0.00206	0.00206	CcSEcCtD
Apraclonidine—Nausea—Epirubicin—liver cancer	0.002	0.002	CcSEcCtD
Apraclonidine—Vomiting—Doxorubicin—liver cancer	0.00198	0.00198	CcSEcCtD
Apraclonidine—Dermatitis—Doxorubicin—liver cancer	0.00196	0.00196	CcSEcCtD
Apraclonidine—Headache—Doxorubicin—liver cancer	0.00195	0.00195	CcSEcCtD
Apraclonidine—Nausea—Doxorubicin—liver cancer	0.00185	0.00185	CcSEcCtD
Apraclonidine—Clonidine—CYP1A1—liver cancer	0.00105	1	CrCbGaD
